Please wait
HEALTHCARE · Pharmaceutical Preparations · Price, fundamentals, signals, and forward-looking context in one research view.
HEALTHCARE
₦243B
1.5%
21.95
Current price
₦93.55
Updated Updated 2h ago
Open
₦99.65
Previous close
₦101.20
Day range
₦99.65 – ₦100.05
Volume
824,861
21.9x P/E
Awaiting filing
1.5% yield
65/100 measured
Moderate liquidity
The latest saved price history for FIDSON, with its range and direction at a glance.
Eye extracted 45 pages. Open the source or continue to Signals for the evidence trail.
Fidson Healthcare Plc manufactures and distributes pharmaceutical products in Nigeria. The company operates in three segments: Over-the-Counter, Ethical Products, and Consumer Healthcare Product. It offers drugs, infusions, capsules, syrups, tablets, and injectables. The company also provides products for anti-infective and anti-malaria, central nervous system, and cough and cold, gastrointestinal medicines; supplements; topical/dermatological medicines; vitamins and minerals; and ophthalmic solutions. Fidson Healthcare Plc was incorporated in 1995 and is headquartered in Lagos, Nigeria.
Investors usually follow FIDSON for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
This official filing has been discovered and is awaiting full extraction or review.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Director dealings
0
Reported buys, sells, and mixed dealings.
Official filings
12
Financial reports and company disclosures captured by Eye.
Market events
0
Insider, filing, dividend, and price events.
Source records
43
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 77/100 while turnover is thin at 0.038%. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Sentiment
Market mood from flow, events, and attention.
ROE
36.1%
Return on equity
ROA
21.0%
Return on assets
Debt / equity
0.78
Lower is usually safer.
P/B ratio
6.93
Useful for book value support.
Dividend yield
1.5%
Current income signal.
76/100
Direction
Cautious
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Valuation still leaves room versus fair value and analyst anchors.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Volatility is elevated, so the path can stay rough even if the thesis is right.
Fair value
₦101.18
Analyst view
n/a
Forecast refresh
Updated 10h ago
Quality score
76
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
22.8
Momentum is weak and the stock is in oversold territory.
Recent trend
Falling
-7.6% across the latest saved price window.
Volatility
Low
Beta is 0.75. Price has historically moved more calmly than the wider market.
52-week position
56% of range
Price is sitting around the middle of its 52-week range.
Volume confirmation
0.95x average
Trading activity is broadly within its normal range.
local manufacturing / import substitution
FIDSON may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
FIDSON may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
FIDSON may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
FIDSON may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
FIDSON may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
increased manufacturing capacity
FIDSON may also move because the HEALTHCARE sector may benefit from increased manufacturing capacity. Confidence 53%.
Neimeth's expansion and completion of a pharmaceutical manufacturing facility will increase production capacity within the healthcare sector.
Halal certification adoption
FIDSON may also move because the HEALTHCARE sector may benefit from halal certification adoption. Confidence 49%.
Halal certification can increase consumer confidence and market access where Halal-compliant products are important, supporting sector trust and accessibility.
FIDSON
Fidson Healthcare Plc
Price: ₦93.55
P/E: 21.95
Yield: 1.5%
EKOCORP
Eko Corporation Plc
Price: ₦5.80
P/E: N/A
Yield: N/A
MAYBAKER
May & Baker Nigeria Plc
Price: ₦40.00
P/E: 14.36
Yield: 1.1%
MECURE
MeCure Industries Plc
Price: ₦56.20
P/E: 31.18
Yield: 0.6%
Industry
Pharmaceutical Preparations
Founded
1995
Employees
732
Exchange
NGX
Ticker
FIDSON
FIDSON HEALTHCARE PLC- QUARTER 2 - FINANCIAL STATEMENT FOR 2026
2026-07-24
Estimated earnings date
2026-05-12
₦2.29B
Book value / share
14.6
